Role of timing of administration in the cardioprotective effect of iloprost, a stable prostacyclln mimetic

Anna Cargnoni, Antonella Boraso, Laura Comini, Federica De Giuli, Enrico Condorelli, Evasio Pasini, Roberta Ferrari

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We administered iloprost, a stable prostacyclin mimetic, 27 nM, to isolated and perfused rabbit hearts submitted, after 60 min of equilibration, to an ischaemic period (60 min at a coronary flow of 1 ml/min) followed by a period of reperfusion (30 min at a coronary flow of 25 ml/min). Iloprost was delivered at different times during the experimental protocol: 60 min before ischaemia, at the onset and after 30 min of ischaemia and only during reperfusion. The iloprost cardioprotective effect was evaluated in terms of recovery of left ventricular pressure developed during reperfusion, creatine phosphokinase (CPK) and noradrenaline release, mitochondrial function (expressed as yield, RCI (respiratory control index), QO2, ADP/O), ATP and creatine phosphate (CP) tissue contents, calcium homeostasis and by measuring several parameters of oxidative stress: reduced and oxidized glutathior e release and tissue contents, Mn and Cu-Zn Superoxide dismutase activities; glutathione reductase and peroxidase activities. Our data show that the cytoprotective action of iloprost is closely related to the time of administration. Optimal myocardial preservation was achieved when it was given before or at the onset of ischaemia. Iloprost administration 30 min after the onset of ischaemia was still beneficial, although to a lesser extent. Iloprost lost its protective effect when given only on reperfusion. The data suggest that the iloprost cardioprotective effect is related to maintainance of membrane integrity.

Original languageEnglish
Pages (from-to)165-178
Number of pages14
JournalEuropean Journal of Pharmacology
Volume199
Issue number2
DOIs
Publication statusPublished - Jun 25 1991

Fingerprint

Iloprost
Reperfusion
Ischemia
Phosphocreatine
Glutathione Reductase
Ventricular Pressure
Epoprostenol
Creatine Kinase
Glutathione Peroxidase
Adenosine Diphosphate
Norepinephrine
Oxidative Stress
Homeostasis
Rabbits
Calcium
Membranes

Keywords

  • Cardioprotection
  • Iloprost
  • Ischaemia (myocardial)
  • Prostacyclin
  • Reperfusion (myocardial)

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Role of timing of administration in the cardioprotective effect of iloprost, a stable prostacyclln mimetic. / Cargnoni, Anna; Boraso, Antonella; Comini, Laura; De Giuli, Federica; Condorelli, Enrico; Pasini, Evasio; Ferrari, Roberta.

In: European Journal of Pharmacology, Vol. 199, No. 2, 25.06.1991, p. 165-178.

Research output: Contribution to journalArticle

Cargnoni, Anna ; Boraso, Antonella ; Comini, Laura ; De Giuli, Federica ; Condorelli, Enrico ; Pasini, Evasio ; Ferrari, Roberta. / Role of timing of administration in the cardioprotective effect of iloprost, a stable prostacyclln mimetic. In: European Journal of Pharmacology. 1991 ; Vol. 199, No. 2. pp. 165-178.
@article{09f23ca85f9a4934a86b3a1725849c1b,
title = "Role of timing of administration in the cardioprotective effect of iloprost, a stable prostacyclln mimetic",
abstract = "We administered iloprost, a stable prostacyclin mimetic, 27 nM, to isolated and perfused rabbit hearts submitted, after 60 min of equilibration, to an ischaemic period (60 min at a coronary flow of 1 ml/min) followed by a period of reperfusion (30 min at a coronary flow of 25 ml/min). Iloprost was delivered at different times during the experimental protocol: 60 min before ischaemia, at the onset and after 30 min of ischaemia and only during reperfusion. The iloprost cardioprotective effect was evaluated in terms of recovery of left ventricular pressure developed during reperfusion, creatine phosphokinase (CPK) and noradrenaline release, mitochondrial function (expressed as yield, RCI (respiratory control index), QO2, ADP/O), ATP and creatine phosphate (CP) tissue contents, calcium homeostasis and by measuring several parameters of oxidative stress: reduced and oxidized glutathior e release and tissue contents, Mn and Cu-Zn Superoxide dismutase activities; glutathione reductase and peroxidase activities. Our data show that the cytoprotective action of iloprost is closely related to the time of administration. Optimal myocardial preservation was achieved when it was given before or at the onset of ischaemia. Iloprost administration 30 min after the onset of ischaemia was still beneficial, although to a lesser extent. Iloprost lost its protective effect when given only on reperfusion. The data suggest that the iloprost cardioprotective effect is related to maintainance of membrane integrity.",
keywords = "Cardioprotection, Iloprost, Ischaemia (myocardial), Prostacyclin, Reperfusion (myocardial)",
author = "Anna Cargnoni and Antonella Boraso and Laura Comini and {De Giuli}, Federica and Enrico Condorelli and Evasio Pasini and Roberta Ferrari",
year = "1991",
month = "6",
day = "25",
doi = "10.1016/0014-2999(91)90454-X",
language = "English",
volume = "199",
pages = "165--178",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Role of timing of administration in the cardioprotective effect of iloprost, a stable prostacyclln mimetic

AU - Cargnoni, Anna

AU - Boraso, Antonella

AU - Comini, Laura

AU - De Giuli, Federica

AU - Condorelli, Enrico

AU - Pasini, Evasio

AU - Ferrari, Roberta

PY - 1991/6/25

Y1 - 1991/6/25

N2 - We administered iloprost, a stable prostacyclin mimetic, 27 nM, to isolated and perfused rabbit hearts submitted, after 60 min of equilibration, to an ischaemic period (60 min at a coronary flow of 1 ml/min) followed by a period of reperfusion (30 min at a coronary flow of 25 ml/min). Iloprost was delivered at different times during the experimental protocol: 60 min before ischaemia, at the onset and after 30 min of ischaemia and only during reperfusion. The iloprost cardioprotective effect was evaluated in terms of recovery of left ventricular pressure developed during reperfusion, creatine phosphokinase (CPK) and noradrenaline release, mitochondrial function (expressed as yield, RCI (respiratory control index), QO2, ADP/O), ATP and creatine phosphate (CP) tissue contents, calcium homeostasis and by measuring several parameters of oxidative stress: reduced and oxidized glutathior e release and tissue contents, Mn and Cu-Zn Superoxide dismutase activities; glutathione reductase and peroxidase activities. Our data show that the cytoprotective action of iloprost is closely related to the time of administration. Optimal myocardial preservation was achieved when it was given before or at the onset of ischaemia. Iloprost administration 30 min after the onset of ischaemia was still beneficial, although to a lesser extent. Iloprost lost its protective effect when given only on reperfusion. The data suggest that the iloprost cardioprotective effect is related to maintainance of membrane integrity.

AB - We administered iloprost, a stable prostacyclin mimetic, 27 nM, to isolated and perfused rabbit hearts submitted, after 60 min of equilibration, to an ischaemic period (60 min at a coronary flow of 1 ml/min) followed by a period of reperfusion (30 min at a coronary flow of 25 ml/min). Iloprost was delivered at different times during the experimental protocol: 60 min before ischaemia, at the onset and after 30 min of ischaemia and only during reperfusion. The iloprost cardioprotective effect was evaluated in terms of recovery of left ventricular pressure developed during reperfusion, creatine phosphokinase (CPK) and noradrenaline release, mitochondrial function (expressed as yield, RCI (respiratory control index), QO2, ADP/O), ATP and creatine phosphate (CP) tissue contents, calcium homeostasis and by measuring several parameters of oxidative stress: reduced and oxidized glutathior e release and tissue contents, Mn and Cu-Zn Superoxide dismutase activities; glutathione reductase and peroxidase activities. Our data show that the cytoprotective action of iloprost is closely related to the time of administration. Optimal myocardial preservation was achieved when it was given before or at the onset of ischaemia. Iloprost administration 30 min after the onset of ischaemia was still beneficial, although to a lesser extent. Iloprost lost its protective effect when given only on reperfusion. The data suggest that the iloprost cardioprotective effect is related to maintainance of membrane integrity.

KW - Cardioprotection

KW - Iloprost

KW - Ischaemia (myocardial)

KW - Prostacyclin

KW - Reperfusion (myocardial)

UR - http://www.scopus.com/inward/record.url?scp=0025765739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025765739&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(91)90454-X

DO - 10.1016/0014-2999(91)90454-X

M3 - Article

C2 - 1720098

AN - SCOPUS:0025765739

VL - 199

SP - 165

EP - 178

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2

ER -